LC
SRPT icon

Lindbrook Capital’s Sarepta Therapeutics SRPT Stock Holding History

Lindbrook Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$13.1K Buy
206
+50
+32% +$5.26K ﹤0.01% 1538
2024
Q4 		$19K Sell
156
-11
-7% -$1.35K ﹤0.01% 1313
2024
Q3 		$20.9K Buy
167
+43
+35% +$5.94K ﹤0.01% 1280
2024
Q2 		$19.6K Sell
124
-15
-11% -$1.93K ﹤0.01% 1251
2024
Q1 		$18K Buy
139
+69
+99% +$8.45K ﹤0.01% 1266
2023
Q4 		$6.75K Buy
70
+28
+67% +$2.69K ﹤0.01% 1733
2023
Q3 		$5.09K Buy
42
+11
+35% +$1.24K ﹤0.01% 1759
2023
Q2 		$3.55K Sell
31
-9
-23% -$1.16K ﹤0.01% 1947
2023
Q1 		$5.51K Buy
40
+12
+43% +$1.56K ﹤0.01% 1815
2022
Q4 		$3.63K Sell
28
-22
-44% -$2.55K ﹤0.01% 1970
2022
Q3 		$6K Buy
+50
New +$5.04K ﹤0.01% 1598
2022
Q1 		– Sell
-49
Closed -$4K – 2609
2021
Q4 		$4K Hold
49
– – ﹤0.01% 1606
2021
Q3 		$5K Buy
49
+42
+600% +$3.23K ﹤0.01% 1260
2021
Q2 		$1K Buy
+7
New +$531 ﹤0.01% 1826
2021
Q1 		– Sell
-11
Closed -$2K – 1940
2020
Q4 		$2K Buy
+11
New +$1.63K ﹤0.01% 1510
2020
Q1 		– Sell
-150
Closed -$19K – 1856
2019
Q4 		$19K Sell
150
-150
-50% -$15.1K 0.01% 762
2019
Q3 		$23K Buy
+300
New +$35.4K 0.01% 658
2019
Q2 		– Sell
-300
Closed -$35K – 1502
2019
Q1 		$35K Buy
+300
New +$38.6K 0.01% 522

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Lindbrook Capital's SRPT Position: Q1 2025 in Review

Lindbrook Capital increased its Sarepta Therapeutics (SRPT) stake by 32% in Q1 2025, buying an estimated $5.26K and bringing the position to 206 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Lindbrook Capital first reported a position in SRPT in Q1 2019 and has held it in 18 quarters since. The position peaked at $35K in Q1 2019. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

  • Lindbrook Capital held 206 shares of Sarepta Therapeutics worth $13.1K as of Q1 2025.
  • Lindbrook Capital bought 50 Sarepta Therapeutics shares in Q1 2025, an estimated $5.26K.
  • Sarepta Therapeutics made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1538 holding.
  • Lindbrook Capital first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 18 quarters since.
  • Lindbrook Capital's Sarepta Therapeutics position peaked at $35K in Q1 2019.
  • 431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.